

1024082

**Section 3**  
**HemosIL Factor VII Deficient Plasma - 510(k) Summary**  
**(Summary of Safety and Effectiveness)**

**Submitted by:**

Instrumentation Laboratory Company  
113 Hartwell Avenue  
Lexington, MA 02421  
Phone: 781-861-4467  
Fax: 781-861-4207

FEB 12 2003

**Contact Person:**

Carol Marble, Regulatory Affairs Director  
Phone: 781-861-4467 / Fax: 781-861-4207

**Summary Prepared:**

December 10, 2002

**Name of the Device:**

HemosIL Factor VII Deficient Plasma

**Classification Name(s):**

864.7290	Factor Deficiency Tests	Class II
81GJT	Plasma, Coagulation Factor Deficient	

**Identification of Predicate Device(s):**

K893535 Hemoliance Factor VII Deficient Plasma on ELECTRA Series Analyzers

K002400 IL Test Factor VII Deficient Plasma\* on ACL Family of Analyzers

\*NOTE: Reagent was 510(k) cleared as part of multiple analyzer systems, most recently the ACL Advance.

**Description of the Device/Intended use(s):**

HemosIL Factor VII Deficient Plasma is human plasma immunodepleted of Factor VII and intended for the *in vitro* diagnostic quantitative determination of Factor VII activity in citrated plasma, based on the prothrombin time (PT) assay, on IL Coagulation and ELECTRA Systems.

Abnormalities of the extrinsic pathway factors are determined by performing a modified prothrombin time (PT) test. Patient plasma is diluted and added to a plasma deficient in Factor VII. Correction of the clotting time of the deficient plasma is proportional to the concentration (% activity) of the Factor VII in the patient plasma, interpolated from a calibration curve.

**Statement of Technological Characteristics of the Device Compared to Predicate Device:**

HemosIL Factor VII Deficient Plasma is substantially equivalent to Hemoliance Factor VII Deficient Plasma (on ELECTRA Series Analyzers) and IL Test Factor VII Deficient Plasma (on ACL Family of Analyzers) in performance, intended use and safety and effectiveness.

### Section 3

## HemosIL Factor VII Deficient Plasma - 510(k) Summary (Summary of Safety and Effectiveness)

### Summary of Performance Data:

#### Method Comparison

In method comparison studies evaluating 60 citrated plasma samples (30 normal/ 30 abnormal), the slopes and correlation coefficients (r) for HemosIL Factor VII Deficient Plasma versus the predicate devices are shown below:

NOTE: HemosIL RecombiPlasTin (K012768) was used as the PT reagent in all testing.

#### HemosIL Factor VII Deficient Plasma vs. Predicate Hemoliance Factor VII Deficient Plasma on ELECTRA

IL System	Slope	r
E1400C	0.9683	0.9967

#### HemosIL Factor VII Deficient Plasma vs. Predicate IL Test Factor VII Deficient Plasma on ACL Family

IL System	Slope	r
ACL 300	1.0045	0.9994
ACL 6000	0.9646	0.9989
ACL 9000	0.9778	0.9996
ACL Futura	0.9678	0.9943

#### Within Run Precision

Within run and total precision assessed over multiple runs (n=80) using two levels of control gave the following results:

Instrument	Control	Mean % Factor VII	Within run CV%	Total CV%
<b>ACL 300</b>	Normal Control	99.6	1.0	2.9
	Low Abnormal Control	49.1	1.2	2.7
<b>ACL 6000</b>	Normal Control	100.5	1.4	1.9
	Low Abnormal Control	49.9	1.5	2.5
<b>ACL 9000</b>	Normal Control	99.4	0.8	2.7
	Low Abnormal Control	47.6	1.4	3.6
<b>ACL Advance</b>	Normal Control	99.9	4.7	5.7
	Low Abnormal Control	50.9	4.6	5.9
<b>ELECTRA 1400C</b>	Normal Control	79.4	2.2	2.7
	Low Abnormal Control	37.8	2.4	3.4



DEPARTMENT OF HEALTH & HUMAN SERVICES

Food and Drug Administration  
2098 Gaither Road  
Rockville MD 20850

Ms. Carol Marble  
Regulatory Affairs Manager  
Instrumentation Laboratory Company  
101 Hartwell Avenue  
Lexington, Massachusetts 02421-3125

FEB 12 2003

Re: k024082  
Trade/Device Name: HemosIL Factor VII Deficient Plasma  
Regulation Number: 21 CFR § 864.7290  
Regulation Name: Plasma, Coagulation Factor Deficient  
Regulatory Class: II  
Product Code: GJT  
Dated: December 10, 2002  
Received: December 11, 2002

Dear Ms. Marble:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.


If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820). This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

Page 2 –

If you desire specific information about the application of labeling requirements to your device, or questions on the promotion and advertising of your device, please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (301) 594-3084. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address <http://www.fda.gov/cdrh/dsma/dsmamain.html>.

Sincerely yours,

A handwritten signature in black ink that reads "Steven Gutman". The signature is written in a cursive, slightly slanted style.

Steven I. Gutman, M.D., M.B.A.  
Director  
Office of In Vitro Diagnostic Device Evaluation and Safety  
Center for Devices and Radiological Health

Enclosure

## Indications for Use Statement

510(k) Number (if known): K024082


**Device Name:** HemosIL Factor VII Deficient Plasma

### Indications for Use:

HemosIL Factor VII Deficient Plasma is human plasma immunodepleted of Factor VII and intended for the *in vitro* diagnostic quantitative determination of Factor VII activity in citrated plasma, based on the prothrombin time (PT) assay, on IL Coagulation and ELECTRA Systems.

(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

  
(Division Sign-Off)  
Division of Clinical Laboratory Devices  
510(k) Number K024082

Prescription Use ☒

OR

Over-The-Counter Use ☐